Potential for Prevention of Inhibitor Formation by Immune Tolerance

ABSTRACT

Factor VIII inhibitory antibodies occur following treatment in more than 30% of subjects with severe factor VIII deficiency. Almost all inhibitor formation occurs in subjects with little if any circulating factor VIII. In the absence of in utero exposure to endogenous or maternal factor VIII, these subjects probably recognize factor VIII as a non-self antigen; in other words, their immune systems fail to become tolerant to factor VIII. This opens up the possibility of preventing inhibitor formation by neonatal induction of tolerance to factor VIII. The various possible approaches include prenatal or neonatal tolerance by the parenteral or oral administration of purified factor VIII protein or factor VIII-encoding DNA. The results of preliminary experiments in mice indicate that feeding newborns a series of low doses of factor VIII does not suppress induction of anti-factor VIII antibody. Whether tolerance can be achieved by feeding mice high doses of factor VIII or by intrauterine or neonatal administration of factor protein or DNA remains to be determined.

KEYWORD

Factor VIII inhibitors - immune tolerance - recombinant human factor VIII - oral tolerance - DNA vaccines

REFERENCES

• 1 Nilsson I M, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.  N Engl J Med . 1988;  318 947-950
• 2 Gruppo R A, Valdez L P, Stout R D. Induction of immune tolerance in patients with hemophilia A and inhibitors.  Am J Pediatr Hematol Oncol . 1992;  14 82-87
• 3 Kreuz W, Becker S, Lenz E. Factor VIII inhibitors in patients with hemophilia A: Epidemiology of inhibitor development and induction of immune tolerance for factor VIII.  Semin Thromb Hemost . 1995;  21 382-389
• 4 Brackmann H H, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' ``Bonn Protocol''.  Vox Sang . 1996;  30-35 (30-35)
• 5 Rocino A, de Biasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.  Vox Sang . 1999;  65-69 (65-69)
• 6 Connelly S, Andrews J L, Gallo A M. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.  Blood . 1998;  91 3273-3281
• 7 Burnett F M, Fenner F. The Production of Antibodies, 2nd ed. London: Macmillan; . 1949: 102-105
• 8 Owen R D. Immunogenic consequences of vascular anastomoses between bovine twins.  Science . 1945;  102 400-401
• 9 Billingham R E, Brent L, Medawar P B. Actively acquired tolerance of foreign cells.  Nature . 1953;  172 603-606
• 10 Triplett E L. On the mechanism of immunologic self recognition.  J Immunol . 1962;  89 505-510
• 11 Hultin M B. Acquired inhibitors in malignant and nonmalignant disease states.  Am J Med . 1991;  91 9S-13S
• 12 Gill F M. The natural history of factor VIII inhibitors in patients with hemophilia A. In: Hoyer LW, ed. Factor VIII Inhibitors, New York: Liss; 1984: 19-29
• 13 Schwaab R, Brackmann H H, Meyer C. Haemophilia mutation type determines risk of inhibitor formation.  Thromb Haemost . 1995;  74 1402-1406
• 14 Peerlinck K, Jacquemin M G, Arnout J. Anti-factor VIII antibody inhibiting hemophilia A.  Blood . 1999;  93 2267-2273
• 15 Aly A M, Aledort L M, Lee T D, Hoyer L W. Antibodies. Histocompatibility antigen patterns in haemophilic patients with factor VIII.  Br J Haematol . 1990;  76 238-241
• 16 Hay C R, Ollier W, Pepper L. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party.  Thromb Haemost . 1997;  77 234-237
• 17 Oldenburg J, Picard J K, Schwaab R. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII.  Thromb Haemost . 1997;  77 238-242
• 18 Ohta H, Takahashi I, Kojima T. Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies.  Tissue Antigens . 1999;  54 91-97
• 19 Gilles J G, Desqueper B, Lenk H, Vermylen J, Saint-Remy J M. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.  J Clin Invest . 1996;  97 1382-1388
• 20 Cinader B. Immunogencity and tolerance to autologous macromolecules. In: Cinader B, ed. Regulation of the Antibody Response Springfield, IL: Charles C Thomas 1968: 3-53
• 21 Nagler-Anderson C, Bober L A, Robinson M E, Siskind G W, Thorbecke G J. Suppression of type II collagen induced arthritis by intragastric administration of soluable type II collagen.  Proc Natl Acad Sci U S A . 1986;  83 7443-7446
• 22 Klinman D M, Takeno M, Ichino M. DNA vaccines: Safety and efficacy issues.  Springer Semin Immunopathol . 1997;  19 245-256
• 23 Strobel S L. Neonatal oral tolerance.  Ann NY Acad Sci . 1996;  778 88-102
• 24 Hanson D G. Ontogeny of orally induced tolerance to soluble proteins in mice. I. Priming and tolerance in newborns.  J Immunol . 1981;  127 1518-1524
• 25 Troncone R, Ferguson A. In mice, gluten in maternal diet primes systemic immune responses to gliadin in offspring.  Immunology . 1988;  64 533-537
• 26 Brown W, Le M, Lee E. Induction of systemic immunologic hyporesponsiveness to ovalbumin in neonatal rats by the enteric administration of peptic fragments of ovalbumin.  Immunol Invest . 1994;  23 73-83
• 27 Velander W H, Lee T K, Scandella D H. Transgenic pigs produce functional human factor VIII in milk.  Nat Biotechnol . 1997;  15 971-975
• 28 Cowdery J S, Curtin Jr F M, Steinberg A D. Effect of prior intragastric antigen administration on primary and secondary anti-ovalbumin responses of C57BL/6 and NZB mice.  J Exp Med . 1982;  156 1256-1261
• 29 Lafont S, Andre C, Andre F, Gillon J, Fargier M C. Abrogation by subsequent feeding of antibody response including IgE, in parenterally immunized mice.  J Exp Med . 1982;  155 1573-1578
• 30 Mor G, Yamshchikov G, Sedegah M. Induction of neonatal tolerance by plasmid DNA vaccination of mice.  J Clin Invest . 1996;  98 2700-2705
• 31 Ichino M, Mor G, Conover J. Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine.  J Immunol . 1999;  162 3814-3818
• 32 Bot A, Antohi S, Bot S, Garcia-Sastre A, Bona C. Induction of humoral and cellular immunity against influenza virus by immunization of newborn mice with a plasmid bearing a hemagglutinin gene.  Int Immunol . 1997;  9 1641-1650
• 33 Manickan E, Yu Z, Rouse B T. DNA immunization of neonates induces immunity despite the presence of maternal antibody.  J Clin Invest . 1997;  100 2371-2375
• 34 Wang Y, Xiang Z, Pasquini S, Ertl H C. Immune response to neonatal genetic immunization.  Virology . 1997;  228 278-284